Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Vor Bio (NASDAQ:VOR), a clinical-stage biotech company focused on autoimmune disease treatments, has announced its participation in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (NASDAQ:VOR), a clinical-stage biotech company focused on autoimmune disease treatments, has announced its participation in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum. The company will engage in a fireside chat on Monday, September 15, 2025, from 4:00-4:25 pm ET in Track 1.
The virtual event will also include one-on-one meetings with investors. Both live webcast and replay of the fireside chat will be accessible through Vor Bio's investor relations website.
Details
News Market Reaction – VOR
On Sep 15, the first trading day after this news, VOR closed 8.05% below the previous close.
Data tracked by StockTitan Argus for the Sep 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.
Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1
Location: Virtual
A live webcast and archived replay of the fireside chat will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.